Prevalence, predisposition and prevention of type II diabetes

Nutrition and Metabolism

Volumn 2, Issue , 2005, Pages

  Cheng, Dong ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; METFORMIN; RIMONABANT; TETRAHYDROLIPSTATIN; TROGLITAZONE;

ARTICLE; BARIATRIC SURGERY; CLINICAL TRIAL; COST OF ILLNESS; DIETARY INTAKE; DISABILITY; DISEASE COURSE; DISEASE PREDISPOSITION; DRUG EFFICACY; DRUG SAFETY; FECES INCONTINENCE; FLATULENCE; HUMAN; IMPAIRED GLUCOSE TOLERANCE; LIFESTYLE; LIVER TOXICITY; METABOLIC SYNDROME X; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PREVALENCE; SITTING; SPOTTING;

EID: 28844503938     PISSN: 17437075     EISSN: 17437075     Source Type: Journal    
DOI: 10.1186/1743-7075-2-29     Document Type: Article

References (117)

1. Centers for Disease Control and Prevention: National diabetes fact sheet: general information and national estimates on diabetes in the United States, 2003. 2003 [http://www.cdc.gov/diabetes/pubs/factsheet.htm]. Acessed at www.cdc.gov/diabetes/pubs/factsheet.htm on June 29th, 2005
2. Zimmet P, Alberti KG, Shaw J: Global and societal implications of the diabetes epidemic. Nature 2001, 414:782-787.
3. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997, 20:1183-1197.
4. Joslin EP: The prevention of diabetes mellitus. JAMA 1921, 76:79-84.
5. Kenny SJ, Aubert RE, Geiss LS: Prevalence and incidence of noninsulin-dependent diabetes. In: Harris MI, Coweie CC, Stern MP et al, eds Diabetes in America National Institute of Health; Washington, DC 1995:47-67.
6. Narayan KM, Boyle JP, Thompson TJ, Sorensen SW, Williamson DF: Lifetime risk for diabetes mellitus in the United States. Jama 2003, 290:1884-1890.
7. Zimmet P, Dowse G, Finch C, Serjeantson S, King H: The epidemiology and natural history of NIDDM-lessons from the South Pacific. Diabetes Metab Rev 1990, 6:91-124.
8. Soderberg S, Zimmet P, Tuomilehto J, de Courten M, Dowse GK, Chitson P, Gareeboo H, Alberti KG, Shaw JE: Increasing prevalence of Type 2 diabetes mellitus in all ethnic groups in Mauritius. Diabet Med 2005, 22:61-68.
9. Pan XR, Yang WY, Li GW, Liu J: Prevalence of diabetes and its risk factors in China, 1994. National Diabetes Prevention and Control Cooperative Group. Diabetes Care 1997, 20:1664-1669.
10. Ramachandran A, Snehalatha C, Baskar AD, Mary S, Kumar CK, Selvam S, Catherine S, Vijay V: Temporal changes in prevalence of diabetes and impaired glucose tolerance associated with lifestyle transition occurring in the rural population in India. Diabetologia 2004, 47:860-865.
11. Alberti G, Zimmet P, Shaw J, Bloomgarden Z, Kaufman F, Silink M: Type 2 diabetes in the young: the evolving epidemic: the international diabetes federation consensus workshop. Diabetes Care 2004, 27:1798-1811.
12. American Diabetes Association: Type 2 diabetes in children and adolescents. American Diabetes Association. Pediatrics 2000, 105:671-680.
13. Songer TJ: The economic costs of NIDDM. Diabetes Metab Rev 1992, 8:389-404.
14. Engelgau MM, Geiss LS, Saaddine JB, Boyle JP, Benjamin SM, Gregg EW, Tierney EF, Rios-Burrows N, Mokdad AH, Ford ES, Imperatore G, Narayan KM: The evolving diabetes burden in the United States. Ann Intern Med 2004, 140:945-950.
15. Mohan V: Why are Indians more prone to diabetes? J Assoc Physicians India 2004, 52:468-474.
16. Bennett PH, Rewers MJ, Knowler WC: Epidemiology of diabetes mellitus. In : Daniel Porte, Jr and Robert S Sherwin edt Ellenberg and Rifkin's Diabetes Mellitus 1996, fifth edition:373-400.
17. Motala AA, Omar MA, Pirie FJ: Diabetes in Africa. Epidemiology of type 1 and type 2 diabetes in Africa. J Cardiovasc Risk 2003, 10:77-83.
18. Rotimi CN, Chen G, Adeyemo AA, Furbert-Harris P, Parish-Gause D, Zhou J, Berg K, Adegoke O, Amoah A, Owusu S, Acheampong J, Agyenim-Boateng K, Eghan BAJ, Oli J, Okafor G, Ofoegbu E, Osotimehin B, Abbiyesuku F, Johnson T, Rufus T, Fasanmade O, Kittles R, Daniel H, Chen Y, Dunston G, Collins FS: A genome-wide search for type 2 diabetes susceptibility genes in West Africans: the Africa America Diabetes Mellitus (AADM) Study. Diabetes 2004, 53:838-841.
19. Dowse GK, Gareeboo H, Zimmet PZ, Alberti KG, Tuomilehto J, Fareed D, Brissonnette LG, Finch CF: High prevalence of NIDDM and impaired glucose tolerance in Indian, Creole, and Chinese Mauritians. Mauritius Noncommunicable Disease Study Group. Diabetes 1990, 39:390-396.
20. Gohdes D: Diabetes in North American Indians and Alaska natives. In: Harris MI, Coweie CC, Stern MP et al, eds Diabetes in America National Institute of Health; Washington, DC 1995:683-702.
21. Flegal KM, Carroll MD, Ogden CL, Johnson CL: Prevalence and trends in obesity among US adults, 1999-2000. Jama 2002, 288:1723-1727.
22. Flegal KM, Carroll MD, Kuczmarski RJ, Johnson CL: Overweight and obesity in the United States: prevalence and trends, 1960-1994. Int J Obes Relat Metab Disord 1998, 22:39-47.
23. Allison DB, Fontaine KR, Manson JE, Stevens J, VanItallie TB: Annual deaths attributable to obesity in the United States. Jama 1999, 282:1530-1538.
24. Thorpe K, Florence C, Howard D: The impact of obesity on rising medical spending. Health Affairs web exclusive 2004, W4:480-486.
25. Kopelman PG: Obesity as a medical problem. Nature 2000, 404:635-643.
26. Hu FB, Manson JE, Stampfer MJ, Colditz G, Liu S, Solomon CG, Willett WC: Diet, lifestyle, and the risk of type 2 diabetes mellitus in women. N Engl J Med 2001, 345:790-797.
27. Stein CJ, Colditz GA: The epidemic of obesity. J Clin Endocrinol Metab 2004, 89:2522-2525.
28. Basciano H, Federico L, Adeli K: Fructose, insulin resistance, and metabolic dyslipidemia. Nutr Metab (Lond) 2005, 2:5.
29. Elliott SS, Keim NL, Stern JS, Teff K, Havel PJ: Fructose, weight gain, and the insulin resistance syndrome. Am J Clin Nutr 2002, 76:911-922.
30. McGarry JD: Banting lecture 2001: dysregulation of fatty acid metabolism in the etiology of type 2 diabetes. Diabetes 2002, 51:7-18.
31. Shulman GI: Unraveling the cellular mechanism of insulin resistance in humans: new insights from magnetic resonance spectroscopy. Physiology (Bethesda) 2004, 19:183-190.
32. Yuan M, Konstantopoulos N, Lee J, Hansen L, Li ZW, Karin M, Shoelson SE: Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta. Science 2001, 293:1673-1677.
33. Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM: IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Science 1996, 271:665-668.
34. Shulman GI: Cellular mechanisms of insulin resistance. J Clin Invest 2000, 106:171-176.
35. Summers SA, Nelson DH: A role for sphingolipids in producing the common features of type 2 diabetes, metabolic syndrome X, and Cushing's syndrome. Diabetes 2005, 54:591-602.
36. Zammit VA: Insulin stimulation of hepatic triacylglycerol secretion in the insulin-replete state: implications for the etiology of peripheral insulin resistance. Ann N Y Acad Sci 2002, 967:52-65.
37. Shimomura I, Matsuda M, Hammer RE, Bashmakov Y, Brown MS, Goldstein JL: Decreased IRS-2 and increased SREBP-1c lead to mixed insulin resistance and sensitivity in livers of lipodystrophic and ob/ob mice. Mol Cell 2000, 6:77-86.
38. Unger RH: Lipotoxicity in the pathogenesis of obesity-dependent NIDDM. Genetic and clinical implications. Diabetes 1995, 44:863-870.
39. Kahn BB, Flier JS: Obesity and insulin resistance. J Clin Invest 2000, 106:473-481.
40. Reaven GM: Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988, 37:1595-1607.
41. Reaven GM: The Insulin Resistance Syndrome: Definition and Dietary Approaches to Treatment. Annu Rev Nutr 2004.
42. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). Jama 2001, 285:2486-2497.
43. World Health Organization: Diabetes Mellitus: Report of a WHO Study Group (WHO, Geneva).
44. Ford ES, Giles WH, Dietz WH: Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. Jama 2002, 287:356-359.
45. Reaven GM: The metabolic syndrome: requiescat in pace. Clin Chem 2005, 51:931-938.
46. Grundy SM: Point: the metabolic syndrome still lives. Clin Chem 2005, 51:1352-1354.
47. Kahn R, Buse J, Ferrannini E, Stern M: The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2005, 28:2289-2304.
48. American Diabetes Association Expert Committee: Report of the Expert Committee. Diabetes Care 1997, 20:1183-1197.
49. American Diabetes Association: Prediabetes. [http://www.diabetes.org/ diabetes-prevention/pre-diabetes.jsp]. Accessed June 20, 2005
50. Shaw JE, Hodge AM, de Courten M, Chitson P, Zimmet PZ: Isolated post-challenge hyperglycaemia confirmed as a risk factor for mortality. Diabetologia 1999, 42:1050-1054.
51. Tominaga M, Eguchi H, Manaka H, Igarashi K, Kato T, Sekikawa A: Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care 1999, 22:920-924.
52. Zimmet PZ, Alberti KG: The changing face of macrovascular disease in non-insulin-dependent diabetes mellitus: an epidemic in progress. Lancet 1997, 350 Suppl 1:SI1-4.
53. Benjamin SM, Valdez R, Geiss LS, Rolka DB, Narayan KM: Estimated number of adults with prediabetes in the US in 2000: opportunities for prevention. Diabetes Care 2003, 26:645-649.
54. Barsh GS, Farooqi IS, O'Rahilly S: Genetics of body-weight regulation. Nature 2000, 404:644-651.
55. O'Rahilly S, Barroso I, Wareham NJ: Genetic factors in type 2 diabetes: the end of the beginning? Science 2005, 307:370-373.
56. Permutt MA, Wasson J, Cox N: Genetic epidemiology of diabetes. J Clin Invest 2005, 115:1431-1439.
57. Pan XR, Li GW, Hu YH, Wang JX, Yang WY, An ZX, Hu ZX, Lin J, Xiao JZ, Cao HB, Liu PA, Jiang XG, Jiang YY, Wang JP, Zheng H, Zhang H, Bennett PH, Howard BV: Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 1997, 20:537-544.
58. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas M, Salminen V, Uusitupa M: Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001, 344:1343-1350.
59. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002, 346:393-403.
60. Ramachandran A, Simon M, Mukesh B, Bhaskar D, Vijay V: Lifestyle modification reduces incident diabetes in Asian Indian with IGT Indian Diabetes Prevention Programme (IDPP1). Diabetes 2005, 54(Suppl 1):A90.
61. American Diabetes Association and National Institute of Diabetes, Digestive and Kidney Disease: The Prevention or Delay of Type 2 Diabetes. Diabetes Care 2002, 25:742-749.
62. Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, Wu M, Ventre J, Doebber T, Fujii N, Musi N, Hirshman MF, Goodyear LJ, Moller DE: Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001, 108:1167-1174.
63. Hardie DG: AMP-activated protein kinase: a key system mediating metabolic responses to exercise. Med Sci Sports Exerc 2004, 36:28-34.
64. Arora SK, Mcfarlane SI: The case for low carbohydrate diets in diabetes managerment. Nutr Metab (Lond) 2005, 2:16.
65. Sears B: Mastering the zone. New York, NY: Harper-Collins Publisher, Inc 1997.
66. Eades ME, Eades MD: Protein Power. New York, NY: Bantam Books 1996.
67. Atkins RC: Dr. Atkins' New Diet Revolution. Rev ed New York, NY: Avon Books 1998.
68. Foster GD, Wyatt HR, Hill JO, McGuckin BG, Brill C, Mohammed BS, Szapary PO, Rader DJ, Edman JS, Klein : A randomized trial of a low-carbohydrate diet for obesity. N Engl J Med 2003, 348(21):2082-2090.
69. Samaha FF, Iqbal N, Seshadri P, Chicano KL, Daily DA, McGrory J, Williams M, Gracely EJ, Stern L: A low-carbohydrate as compared with a low-fat diet in severe obesity. N Engl J Med 2003, 348(21):2074-2081.
70. Volek JS, Sharman MJ, Gomez AL, Judelson DA, Rubin MR, Watson G, Sokmen B, Silvestre R, French DN, Kraemer WJ: Comparison of energy-restricted very low-carbohydrate and low-fat diets on weight loss and body composition in overweight men and women. Nutr Metab (Lond) 2004, 1(1):13.
71. Boden G, Sargrad K, Homko C, Mozzoli M, Stein TP: Effect of a low-carbohydrate diet on appetite, blood glucose levels, and insulin resistance in obese patients with type 2 diabetes. Ann Intern Med 2005, 142:403-411.
72. Gannon MC, Nuttall FQ: Effect of a high-protein, low-carbohydrate diet on blood glucose control in people with type 2 diabetes. Diabetes 2004, 53:2375-2382.
73. Long SD, O'Brien K, MacDonald KGJ, Leggett-Frazier N, Swanson MS, Pories WJ, Caro JF: Weight loss in severely obese subjects prevents the progression of impaired glucose tolerance to type II diabetes. A longitudinal interventional study. Diabetes Care 1994, 17:372-375.
74. Sjostrom CD, Peltonen M, Wedel H, Sjostrom L: Differentiated long-term effects of intentional weight loss on diabetes and hypertension. Hypertension 2000, 36:20-25.
75. Goldstein DJ: Beneficial health effects of modest weight loss. Int J Obes Relat Metab Disord 1992, 16:397-415.
76. Rissanen A: Pharmacological intervention: the antiobesity approach. Eur J Clin Invest 1998, 28 Suppl 2:27-30.
77. Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L: XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004, 27:155-161.
78. Hollander PA, Elbein SC, Hirsch IB, Kelley D, McGill J, Taylor T, Weiss SR, Crockett SE, Kaplan RA, Comstock J, Lucas CP, Lodewick PA, Canovatchel W, Chung J, Hauptman J: Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study. Diabetes Care 1998, 21:1288-1294.
79. Simiand J, Keane M, Keane PE, Soubrie P: SR 141716, a CB1 cannabinoid receptor antagonist, selectively reduces sweet food intake in marmoset. Behav Pharmacol 1998, 9:179-181.
80. Colombo G, Agabio R, Diaz G, Lobina C, Reali R, Gessa GL: Appetite suppression and weight loss after the cannabinoid antagonist SR 141716. Life Sci 1998, 63:PL113-7.
81. Vickers SP, Webster LJ, Wyatt A, Dourish CT, Kennett GA: Preferential effects of the cannabinoid CB1 receptor antagonist, SR 141716, on food intake and body weight gain of obese (fa/fa) compared to lean Zucker rats. Psychopharmacology (Berl) 2003, 167:103-111.
82. Osei-Hyiaman D, DePetrillo M, Pacher P, Liu J, Radaeva S, Batkai S, Harvey-White J, Mackie K, Offertaler L, Wang L, Kunos G: Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest 2005, 115:1298-1305.
83. Bensaid M, Gary-Bobo M, Esclangon A, Maffrand JP, Le Fur G, Oury-Donat F, Soubrie P: The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol Pharmacol 2003, 63:908-914.
84. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S: Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005, 365:1389-1397.
85. The Diabetes Prevention Program. Design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care 1999, 22:623-634.
86. Knowler WC, Hamman RF, Edelstein SL, Barrett-Connor E, Ehrmann DA, Walker EA, Fowler SE, Nathan DM, Kahn SE: Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program. Diabetes 2005, 54:1150-1156.
87. Buchanan TA, Xiang AH, Peters RK, Kjos SL, Marroquin A, Goico J, Ochoa C, Tan S, Berkowitz K, Hodis HN, Azen SP: Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women. Diabetes 2002, 51:2796-2803.
88. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M: Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002, 359:2072-2077.
89. Mojsov S, Weir GC, Habener JF: Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas. J Clin Invest 1987, 79:616-619.
90. Deacon CF: Therapeutic strategies based on glucagon-like peptide 1. Diabetes 2004, 53:2181-2189.
91. Egan JM, Meneilly GS, Elahi D: Effects of 1-mo bolus subcutaneous administration of exendin-4 in type 2 diabetes. Am J Physiol Endocrinol Metab 2003, 284:E1072-9.
92. Baron A, Poon T, Taylor K, Nielsen L, Boies S, Zhou J, Zhuang D, Varns A, Kim D, Fineman M, Kolterman O: Exenadite (synthetic extendin-4) showed marked HbA1c decline over 5 months in patients with type 2 diabetes failing oral agents in an openlabel study. Presented at the 63rd Scientific Sessions of the American Diabetes Association, New Orleans, LA, 13-17 June 2003 (late breaking abstract 3-LB) 2003.
93. Ahren B, Simonsson E, Larsson H, Landin-Olsson M, Torgeirsson H, Jansson PA, Sandqvist M, Bavenholm P, Efendic S, Eriksson JW, Dickinson S, Holmes D: Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes. Diabetes Care 2002, 25:869-875.
94. Tyroler HA: Cholesterol and cardiovascular disease. An overview of Lipid Research Clinics (LRC) epidemiologic studies as background for the LRC Coronary Primary Prevention Trial. Am J Cardiol 1984, 54(5):14C-19C.
95. Hebert PR, Gaziano JM, Chan KS, Hennekens CH: Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. Jama 1997, 278:313-321.
96. Pharoah PD, Hollingworth W: Cost effectiveness of lowering cholesterol concentration with statins in patients with and without pre-existing coronary heart disease: life table method applied to health authority population. Bmj 1996, 312:1443-1448.
97. Inoue H, Ferrer J, Welling CM, Elbein SC, Hoffman M, Mayorga R, Warren-Perry M, Zhang Y, Millns H, Turner R, Province M, Bryan J, Permutt MA, Aguilar-Bryan L: Sequence variants in the sulfonylurea receptor (SUR) gene are associated with NIDDM in Caucasians. Diabetes 1996, 45:825-831.
98. Hani EH, Clement K, Velho G, Vionnet N, Hager J, Philippi A, Dina C, Inoue H, Permutt MA, Basdevant A, North M, Demenais F, Guy-Grand B, Froguel P: Genetic studies of the sulfonylurea receptor gene locus in NIDDM and in morbid obesity among French Caucasians. Diabetes 1997, 46:688-694.
99. Horikawa Y, Oda N, Cox NJ, Li X, Orho-Melander M, Hara M, Hinokio Y, Lindner TH, Mashima H, Schwarz PE, del Bosque-Plata L, Oda Y, Yoshiuchi I, Colilla S, Polonsky KS, Wei S, Concannon P, Iwasaki N, Schulze J, Baier LJ, Bogardus C, Groop L, Boerwinkle E, Hanis CL, Bell GI: Genetic variation in the gene encoding calpain-10 is associated with type 2 diabetes mellitus. Nat Genet 2000, 26:163-175.
100. Weedon MN, Schwarz PE, Horikawa Y, Iwasaki N, Illig T, Holle R, Rathmann W, Selisko T, Schulze J, Owen KR, Evans J, Del Bosque-Plata L, Hitman G, Walker M, Levy JC, Sampson M, Bell GI, McCarthy MI, Hattersley AT, Frayling TM: Meta-analysis and a large association study confirm a role for calpain-10 variation in type 2 diabetes susceptibility. Am J Hum Genet 2003, 73:1208-1212.
101. Hager J, Hansen L, Vaisse C, Vionnet N, Philippi A, Poller W, Velho G, Carcassi C, Contu L, Julier C, Cambien F, Passa P, Lathrop M, Kindsvogel W, Demenais F, Nishimura E, Froguel P: A missense mutation in the glucagon receptor gene is associated with non-insulin-dependent diabetes mellitus. Nature Genetics 9 1995, 9:299-394.
102. McCarthy MI, Hitman GA, Hitchins M, Riikonen A, Stengard J, Nissinen A, Tuomilehto-Wolf E, Tuomilehto J: Glucokinase gene polymorphisms: a genetic marker for glucose intolerance in a cohort of elderly Finnish men. Diabet Med 1994, 11:198-204.
103. Hani EH, Boutin P, Durand E, Inoue H, Permutt MA, Velho G, Froguel P: Missense mutations in the pancreatic islet beta cell inwardly rectifying K+ channel gene (KIR6.2/BIR): a meta-analysis suggests a role in the polygenic basis of Type II diabetes mellitus in Caucasians. Diabetologia 1998, 41:1511-1515.
104. Deeb SS, Fajas L, Nemoto M, Pihlajamaki J, Mykkanen L, Kuusisto J, Laakso M, Fujimoto W, Auwerx J: A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet 1998, 20:284-287.
105. Yamagata K, Furuta H, Oda N, Kaisaki PJ, Menzel S, Cox NJ, Fajans SS, Signorini S, Stoffel M, Bell GI: Mutations in the hepatocyte nuclear factor-4alpha gene in maturity-onset diabetes of the young (MODY1). Nature 1996, 384:458-460.
106. Yamagata K, Oda N, Kaisaki PJ, Menzel S, Furuta H, Vaxillaire M, Southam L, Cox RD, Lathrop GM, Boriraj VV, Chen X, Cox NJ, Oda Y, Yano H, Le Beau MM, Yamada S, Nishigori H, Takeda J, Fajans SS, Hattersley AT, Iwasaki N, Hansen T, Pedersen O, Polonsky KS, Bell GI, et al.: Mutations in the hepatocyte nuclear factor-1alpha gene in maturity-onset diabetes of the young (MODY3). Nature 1996, 384:455-458.
107. Li SR, Baroni MG, Oelbaum RS, Stock J, Galton DJ: Association of genetic variant of the glucose transporter with non-insulin-dependent diabetes mellitus. Lancet 1988, 2:368-370.
108. Huxtable SJ, Saker PJ, Haddad L, Walker M, Frayling TM, Levy JC, Hitman GA, O'Rahilly S, Hattersley AT, McCarthy MI: Analysis of parent-offspring trios provides evidence for linkage and association between the insulin gene and type 2 diabetes mediated exclusively through paternally transmitted class III variable number tandem repeat alleles. Diabetes 2000, 49:126-130.
109. Kadowaki T, Bevins CL, Cama A, Ojamaa K, Marcus-Samuels B, Kadowaki H, Beitz L, McKeon C, Taylor SI: Two mutant alleles of the insulin receptor gene in a patient with extreme insulin resistance. Science 1988, 240:787-790.
110. Taylor SI, Kadowaki T, Kadowaki H, Accili D, Cama A, McKeon C: Mutations in insulin-receptor gene in insulin-resistant patients. Diabetes Care 1990, 13:257-279.
111. Poulton J, Luan J, Macaulay V, Hennings S, Mitchell J, Wareham NJ: Type 2 diabetes is associated with a common mitochondrial variant: evidence from a population-based case-control study. Hum Mol Genet 2002, 11:1581-1583.
112. Clement K, Vaisse C, Lahlou N, Cabrol S, Pelloux V, Cassuto D, Gourmelen M, Dina C, Chambaz J, Lacorte JM, Basdevant A, Bougneres P, Lebouc Y, Froguel P, Guy-Grand B: A mutation in the human leptin receptor gene causes obesity and pituitary dysfunction. Nature 1998, 392:398-401.
113. Yeo GS, Farooqi IS, Aminian S, Halsall DJ, Stanhope RG, O'Rahilly S: A frameshift mutation in MC4R associated with dominantly inherited human obesity. Nat Genet 1998, 20:111-112.
114. Montague CT, Farooqi IS, Whitehead JP, Soos MA, Rau H, Wareham NJ, Sewter CP, Digby JE, Mohammed SN, Hurst JA, Cheetham CH, Earley AR, Barnett AH, Prins JB, O'Rahilly S: Congenital leptin deficiency is associated with severe early-onset obesity in humans. Nature 1997, 387:903-908.
115. Jackson RS, Creemers JW, Ohagi S, Raffin-Sanson ML, Sanders L, Montague CT, Hutton JC, O'Rahilly S: Obesity and impaired prohormone processing associated with mutations in the human prohormone convertase 1 gene. Nat Genet 1997, 16:303-306.
116. Krude H, Biebermann H, Luck W, Horn R, Brabant G, Gruters A: Severe early-onset obesity, adrenal insufficiency and red hair pigmentation caused by POMC mutations in humans. Nat Genet 1998, 19:155-157.
117. Suviolahti E, Oksanen LJ, Ohman M, Cantor RM, Ridderstrale M, Tuomi T, Kaprio J, Rissanen A, Mustajoki P, Jousilahti P, Vartiainen E, Silander K, Kilpikari R, Salomaa V, Groop L, Kontula K, Peltonen L, Pajukanta P: The SLC6A14 gene shows evidence of association with obesity. J Clin Invest 2003, 112:1762-1772.